We are live on ! Find out more
XERS icon

Xeris Biopharma Holdings
XERS

92 hedge funds and large institutions have $120M invested in Xeris Biopharma Holdings in 2021 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 33 increasing their positions, 15 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more call options, than puts

Call options by funds: $6.72M | Put options by funds: $1.92M

230% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 10

180% more capital invested

Capital invested by funds: $42.9M → $120M (+$77.3M)

120% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 15

31% more funds holding

Funds holding: 70 → 92 (+22)

6.58% more ownership

Funds ownership: 26.34% → 32.91% (+6.6%)

Holders
92
Holders Change
+22
Holders Change %
+31.43%
% of All Funds
1.42%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
33
Increased
33
Reduced
15
Closed
10
Calls
$6.72M
Puts
$1.92M
Net Calls
+$4.8M
Net Calls Change
+$736K

Top Buyers

Rank Fund Capital Flow
1
CC
Caxton Corporation
New Jersey
+$13.6M
2
SCM
Stonepine Capital Management
Oregon
+$12.2M
3
NMC
NEA Management Company
Maryland
+$7.02M
4
Lazard Asset Management
Lazard Asset Management
New York
+$5.03M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$4.62M

Top Sellers

Rank Fund Capital Flow
1
SC
Sessa Capital
New York
-$8.97M
2
RG
Redmile Group
California
-$674K
3
BCM
Bridgeway Capital Management
Texas
-$346K
4
SFI
Susquehanna Fundamental Investments
Pennsylvania
-$190K
5
AGM
Alpine Global Management
New York
-$162K
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
1
Caxton Corporation
New Jersey
$18.5M +$13.6M +6,310,546 New
SCM
2
Stonepine Capital Management
Oregon
$16.6M +$12.2M +5,656,373 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$15M +$4.62M +2,139,443 +72%
NMC
4
NEA Management Company
Maryland
$9.52M +$7.02M +3,250,000 New
Lazard Asset Management
5
Lazard Asset Management
New York
$7.27M +$5.03M +2,330,568 +1,553%
Invesco
6
Invesco
Georgia
$5.97M -$1.49K -688 -0%
BlackRock
7
BlackRock
New York
$5.26M +$583K +269,705 +18%
Man Group
8
Man Group
United Kingdom
$4.86M +$3.5M +1,622,040 +4,456%
Morgan Stanley
9
Morgan Stanley
New York
$3.96M +$2.39M +1,104,830 +449%
RG
10
Redmile Group
California
$3.07M -$674K -312,238 -23%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$2.94M +$650K +300,830 +43%
Tudor Investment Corp
12
Tudor Investment Corp
Connecticut
$2.81M +$2.07M +960,111 New
Renaissance Technologies
13
Renaissance Technologies
New York
$2.58M +$1.59M +738,182 +520%
Susquehanna International Group
14
Susquehanna International Group
Pennsylvania
$2.44M +$486K +225,009 +37%
GIM
15
Granahan Investment Management
Massachusetts
$1.54M +$129K +59,563 +13%
DAM
16
Deltec Asset Management
New York
$1.2M -$107K -49,500 -11%
State Street
17
State Street
Massachusetts
$1.07M +$323K +149,627 +69%
IWM
18
IHT Wealth Management
Illinois
$1M +$18.4K +8,530 +3%
Simplex Trading
19
Simplex Trading
Illinois
$941K +$666K +308,466 +2,386%
CSS
20
Cubist Systematic Strategies
Connecticut
$914K +$636K +294,251 +1,677%
Brown Advisory
21
Brown Advisory
Maryland
$878K +$647K +299,754 New
AGM
22
Alpine Global Management
New York
$864K -$162K -75,000 -20%
BCM
23
Bridgeway Capital Management
Texas
$710K -$346K -160,149 -40%
Goldman Sachs
24
Goldman Sachs
New York
$667K +$224K +103,507 +83%
Millennium Management
25
Millennium Management
New York
$649K -$10K -4,643 -2%
1
2 3 4

XERS Hedge Fund Activity: Q4 2021 in Review

92 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q4 2021, worth a combined $120M — up 180% from $42.9M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new XERS positions and 10 closed out — a net gain of 23 holders — while 33 added to existing stakes and 15 trimmed.

The largest buyer was Caxton Corporation, opening a new position worth an estimated $13.6M. The largest seller was Sessa Capital, exiting entirely with an estimated $8.97M sold.

  • 92 institutional investors held Xeris Biopharma Holdings (XERS) as of Q4 2021, up from 70 in Q3 2021.
  • Funds reported $120M of Xeris Biopharma Holdings stock for Q4 2021, up 180% quarter-over-quarter.
  • 33 funds opened new Xeris Biopharma Holdings positions in Q4 2021 and 10 closed out, a net change of +23 holders.
  • The largest Xeris Biopharma Holdings buyer in Q4 2021 was Caxton Corporation, an estimated $13.6M added.
  • The largest Xeris Biopharma Holdings seller in Q4 2021 was Sessa Capital, an estimated $8.97M sold.

Based on aggregated 13F filings for Q4 2021.